Business
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif., May 14, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.
About this update from Alto Neuroscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1659,"height":537,"url":"https://media.zenfs.com/en/business-wire.com/968913049b3a61c4a6f209941422bf42"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_Fimw.WJdYYLnD0RxxsVsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/968913049b3a61c4a6f209941422bf42","width":960,"height":311},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/dFnCaqloZef0Z0fy1zaUpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/968913049b3a61c4a6f209941422bf42","width":1200,"height":388}},"lazy":false},{"type":"text","content":"– Phase 2 proof-of-concept trials remain on track: Topline data expected from ALTO-203 in MDD in the second quarter of 2025 followed by ALTO-101 in schizophrenia in the second half of 2025 –","length":190,"tagName":"p","attribs":{}},{"type":"text","content":"– Late-stage programs advancing: Topline data expected from the Phase 2b trial of ALTO-300 in MDD in mid-2026 followed by the Phase 2b trial of ALTO-100 in bipolar depression in the second half of 2026 –","length":203,"tagName":"p","attribs":{}},{"type":"text","content":"– New data presented at recent scientific conferences support Alto’s biomarker-driven pipeline and patient stratification approach –","length":132,"tagName":"p","attribs":{}},{"type":"text","content":"– Strong cash position of approximately $161.3 million expected to fund planned operations into 2028, and through at least four upcoming clinical study readouts –","length":162,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., May 14, 2025--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.","length":407,"tagName":"p"},{"type":"text","content":""In the first quarter of 2025 we took important steps to deliver on our clinical and corporate objectives," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neurosci...